All Stories

  1. Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?
  2. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment Af...
  3. Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program
  4. Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?
  5. How can we optimize the processes of care for acute coronary syndromes to improve outcomes?
  6. Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: The DEMONSTRATE study
  7. TCT-645 Optical coherence tomography findings in bioresorbable scaffold thrombosis
  8. Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)
  9. Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implem...
  10. Stable Angina Pectoris
  11. Predicting 3-Year Mortality After Percutaneous Coronary Intervention
  12. Transradial Coronary Catheterization and Intervention Across the Whole Spectrum of Allen Test Results
  13. Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy
  14. Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial
  15. PROGNOSTIC IMPLICATIONS OF SEVERE LESION CALCIFICATION IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
  16. Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry
  17. Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the Women–Drug-Eluting stent for LefT main coronary Artery disease ...
  18. Tirofiban
  19. Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis
  20. Long‐term outcome in patients with ST segment elevation myocardial infarction and multivessel disease treated with culprit‐only, immediate, or staged multivessel percutaneous revascularization strategies: Insights from the REAL registry
  21. Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable
  22. Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial
  23. Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary Intervention
  24. Acute kidney injury after primary angioplasty
  25. The EXAMINATION Trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction)
  26. Excimer Laser LEsion Modification to Expand Non-dilatable sTents: The ELLEMENT Registry
  27. Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction
  28. Meeting the Unmet – The Cre8 Polymer-free Drug-eluting Stents Technology
  29. Identifying responsiveness to oral P2Y12 receptor blockers
  30. Zotarolimus- Versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease
  31. Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected Left Main Coronary Artery
  32. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials
  33. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint ...
  34. Comparison of Bivalirudin Versus Heparin(s) During Percutaneous Coronary Interventions in Patients Receiving Prasugrel: A Propensity‐Matched Study
  35. Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: A meta-analysis of randomized trials
  36. TCT-242 Impact of gender on clinical outcome of everolimus-eluting stent versus bare-metal stent in patients with ST-elevation myocardial infarction.
  37. TCT-447 Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction. Insights from the EXAMINATION trial
  38. Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction
  39. 5-S-Lipoylhydroxytyrosol, a Multidefense Antioxidant Featuring a Solvent-Tunable Peroxyl Radical-Scavenging 3-Thio-1,2-dihydroxybenzene Motif
  40. Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients
  41. Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] Study)
  42. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis
  43. Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction
  44. Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction
  45. Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
  46. Migratory activity of circulating progenitor cells and serum SDF-1α predict adverse events in patients with myocardial infarction
  47. Open-Label, Randomized, Placebo-Controlled Evaluation of Intracoronary Adenosine or Nitroprusside After Thrombus Aspiration During Primary Percutaneous Coronary Intervention for the Prevention of Microvascular Obstruction in Acute Myocardial Infarction
  48. Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY)
  49. DETERMINATION OF THE URINARY NEUTROPHIL GELATINASE–ASSOCIATED LIPOCALIN AS AN EARLY MARKER OF CONTRAST INDUCED ACUTE KIDNEY INJURY AFTER CORONARY CATHETERIZATION
  50. ARE “NEW GENERATION” DES SUPERIOR TO “OLD GENERATION” DES IN REDUCING ADVERSE CLINICAL OUTCOMES AT LONG–TERM FOLLOW–UP: INSIGHTS FROM REAL (REGISTRO REGIONALE ANGIOPLASTICHE DELL'EMILIA–ROMAGNA) MULTICENTER REGISTRY
  51. PREDICTION OF ONE-YEAR MORTALITY IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PCI FROM THE ACUITY (ACUTE CATHETERIZATION AND URGENT INTERVENTION TRIAGE STRATEGY) TRIAL VALIDATION OF THE LOGISTIC CLINICAL SYNTAX SCORE
  52. THE ROLE OF FEMALE SEX IN THE CONTEMPORARY TREATMENT OF THE LEFT MAIN CORONARY ARTERY INSIGHTS FROM THE W– DELTA (WOMEN– DRUG ELUTING STENT FOR LEFT MAIN CORONARY ARTERY DISEASE) REGISTRY
  53. Deferred angioplasty and stenting in primary percutaneous coronary intervention: one step back, two steps forward?
  54. A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial
  55. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation
  56. Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST
  57. Letter by Cortese and Valgimigli Regarding Article, “Antithrombotic Therapy in Patients With Chronic Kidney Disease”
  58. Letter by Vranckx and Valgimigli Regarding Article, “Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention”
  59. Glycoprotein IIb/IIIa Inhibitors
  60. TCT-747 Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis
  61. TCT-481 Comparison of newer generation drug-eluting stents with bare metal stents in patients with acute ST-segment elevation myocardial infarction: A pooled analysis of EXAMINATION and COMFORTABLE AMI trials
  62. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial
  63. Peri-procedural myocardial infarction and troponism: a quick journey through the land of confusion
  64. Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study
  65. Drug-Eluting Stent for Left Main Coronary Artery Disease
  66. Reply
  67. Does the site of bleeding matter? A stratified analysis on Flocation of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction
  68. Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: The INtegrilin plus STenting to Avoid myocardial Necrosis Trial
  69. Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: A meta-analysis of randomized trials
  70. A DOUBLE BLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY OF BINDARIT IN PREVENTING CORONARY STENT RESTENOSIS
  71. Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting
  72. COMBINED ANATOMICAL AND CLINICAL FACTORS FOR THE RISK STRATIFICATION OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: THE LOGISTIC CLINICAL SYNTAX SCORE
  73. PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL
  74. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
  75. Transradial Versus Transfemoral Intervention for Acute Myocardial Infarction
  76. Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofib...
  77. A1M
  78. AAA
  79. AAST Spleen Injury Scale
  80. Abbreviated Injury Scale
  81. Abbreviated Laparotomy
  82. ABCDEs
  83. Abdominal Aortic Aneurysm
  84. Abdominal Aortic Aneurysm: Diagnosis and Management
  85. Reply
  86. Clinical dilemmas on managing antiplatelet therapies after percutaneous coronary intervention
  87. Dual antiplatelet therapy duration
  88. Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction
  89. Cardiovascular risk profile of patients included in stent trials; a pooled analysis of individual patient data from randomised clinical trials: insights from 33 prospective stent trials in Europe
  90. Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention
  91. Early Angio-Guided Complete Revascularization versus Culprit Vessel PCI Followed by Ischemia-Guided Staged PCI in STEMI Patients with Multivessel Disease
  92. Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials
  93. Triple Antiplatelet Therapy in Acute Coronary Syndromes
  94. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes
  95. AMI on the move
  96. Looking back into the future: desirudin in acute coronary syndromes and coronary stenting
  97. Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention
  98. A Patient-Level Pooled Analysis Assessing the Impact of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) Score on 1-Year Clinical Outcomes in 6,508 Patients Enrolled in Contemporary Coronary Stent Trials
  99. Genetic determinants of on-clopidogrel high platelet reactivity
  100. Zotarolimus Eluting Stent Clinical Studies
  101. IMPACT OF CLOPIDOGREL ON-TREATMENT PLATELET REACTIVITY ON STENT THROMBOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION: RESULTS FROM A COLLABORATIVE META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA
  102. Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention
  103. Different clinical models of CD34 + cells mobilization in patients with cardiovascular disease
  104. Prediction of 1-Year Clinical Outcomes Using the SYNTAX Score in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
  105. Persistent Coronary No Flow After Wire Insertion Is an Early and Readily Available Mortality Risk Factor Despite Successful Mechanical Intervention in Acute Myocardial Infarction
  106. Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: Balancing safety and efficacy
  107. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention
  108. Long-Term Clinical Outcome Based on Aspirin and Clopidogrel Responsiveness Status After Elective Percutaneous Coronary Intervention
  109. Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome
  110. Safety evaluation of tirofiban
  111. Long-Term Clinical Results Following Stenting of the Left Main Stem
  112. Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update
  113. Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials
  114. ONE-YEAR OUTCOMES AFTER TIROFIBAN VERSUS ABCIXIMAB INFUSION IN 745 PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PRIMARY INTERVENTION: INSIGHTS FROM THE MLTISTRATEGY TRIAL
  115. Poor response to clopidogrel: current and future options for its management
  116. Evaluation of Platelet Inhibition by Tirofiban in Patients Stratified According to Aspirin and Clopidogrel Responsiveness
  117. The 5-Year Clinical Outcomes After a Randomized Comparison of Sirolimus-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction
  118. Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?
  119. PCV115 TIROFIBAN IS MORE COST-EFFICIENT THAN ABCIXIMAB IN ACHIEVING ST-SEGMENT RESOLUTION FOLLOWING ACUTE MYOCARDIAL INFARCTION
  120. Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol
  121. Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting
  122. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials
  123. Drug-Eluting Stents Versus Bare-Metal Stents in Diabetic Patients With ST-Segment Elevation Acute Myocardial Infarction: A Pooled Analysis of Individual Patient Data From 7 Randomized Trials
  124. Stents liberadores de fármacos frente a stents convencionales en pacientes diabéticos con infarto agudo de miocardio con elevación del segmento ST: un análisis combinado de los datos de pacientes individuales de 7 ensayos aleatorizados
  125. Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials
  126. Assisted circulation using the TandemHeart® during very high-risk PCI of the unprotected left main coronary artery in patients declined for CABG
  127. Defining the Role of Platelet Glycoprotein Receptor Inhibitors in STEMI
  128. Beneficial Effect of the Nonpeptidyl Low Molecular Weight Radical Scavenger IAC on Cultured Human Islet Function
  129. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial
  130. A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction
  131. Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Disease: The Endless Debate
  132. Carotid Stent Cell Design: Lack of Benefit or Lack of Evidence?
  133. Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design
  134. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial
  135. Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease
  136. Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The Diabetes and Drug Eluting stent for LeFT main registry (D-DELFT)
  137. Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial InfarctionThe MULTISTRATEGY Randomized Trial
  138. Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction
  139. Effects of Percutaneous Transluminal Septal Myocardial Ablation for Obstructive Hypertrophic Cardiomyopathy on Systolic and Diastolic Left Ventricular Function Assessed by Pressure–Volume Loops
  140. Abciximab: a reappraisal of its use in coronary care
  141. Reply
  142. Use of granulocyte colony-stimulating factor during acute MI: Fact or fiction?
  143. A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease
  144. Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention††Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker’s bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aven...
  145. Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?
  146. Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction
  147. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction
  148. Poor responsiveness to clopidogrel. Drug-specific or class-effect?
  149. Acute coronary syndromes: an emphasis shift from treatment to prevention; and the enduring challenge of vulnerable plaque detection in the cardiac catheterization laboratory
  150. Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: Evidence from a meta-regression
  151. Cyphering the Complexity of Coronary Artery Disease Using the Syntax Score to Predict Clinical Outcome in Patients With Three-Vessel Lumen Obstruction Undergoing Percutaneous Coronary Intervention
  152. The heart of coronary arteries
  153. Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
  154. Keeping a high standard in quantitative analyses, meta-analyses, and systematic reviews
  155. Clinical Implications of the PROTECT–TIMI-30 Trial
  156. Plaque sealing: Are the benefits outweighing the risks?
  157. Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients
  158. Plaque Composition in the Left Main Stem Mimics the Distal But Not the Proximal Tract of the Left Coronary Artery
  159. Impact of Stable Versus Unstable Coronary Artery Disease on 1-Year Outcome in Elective Patients Undergoing Multivessel Revascularization With Sirolimus-Eluting Stents
  160. Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention
  161. Diagnostic Performance of Multislice Spiral Computed Tomography of Coronary Arteries as Compared With Conventional Invasive Coronary Angiography
  162. Single-vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era. Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RE...
  163. Stress and tissue Doppler echocardiographic evidence of effectiveness of myoblast transplantation in patients with ischaemic heart failure
  164. Stem Cell Delivery Modalities
  165. Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radio frequency data analysis, is related to clinical presentation
  166. In vivo relationship between compositional and mechanical imaging of coronary arteries
  167. Long-Term Outcomes After Stenting of Bifurcation Lesions With the “Crush” Technique
  168. Distal Left Main Coronary Disease Is a Major Predictor of Outcome in Patients Undergoing Percutaneous Intervention in the Drug-Eluting Stent Era
  169. Persistence of Neointimal Growth 12 Months After Intervention and Occurrence of Delayed Restenosis in Patients With Left Main Coronary Artery Disease Treated With Drug-Eluting Stents
  170. Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for the design of longitudinal studies
  171. Is Late Luminal Loss an Accurate Predictor of the Clinical Effectiveness of Drug-Eluting Stents in the Coronary Arteries?
  172. Intramyocardial injection of skeletal myoblasts: long-term follow-up with pressure–volume loops
  173. Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: Insights from a systematic overview of randomized trials in light of the drug-eluting stent era
  174. Noninvasive Detection of Subclinical Coronary Atherosclerosis Coupled With Assessment of Changes in Plaque Characteristics Using Novel Invasive Imaging Modalities
  175. Plaque Composition and its Relationship With Acknowledged Shear Stress Patterns in Coronary Arteries
  176. Sirolimus-Eluting Versus Paclitaxel-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease
  177. Distance from the ostium as an independent determinant of coronary plaque composition in vivo: an intravascular ultrasound study based radiofrequency data analysis in humans
  178. Revisiting late loss and neointimal volumetric measurements in a drug‐eluting stent trial: Analysis from the SPIRIT FIRST trial
  179. Drawbacks of Nonrandomized Trials in Acute Coronary Syndromes
  180. Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives
  181. Commentary
  182. In Vivo Intravascular Ultrasound-Derived Thin-Cap Fibroatheroma Detection Using Ultrasound Radiofrequency Data Analysis
  183. “Full metal jacket” (stented length ≥64 mm) using drug-eluting stents for de novo coronary artery lesions
  184. Letter Regarding Article by Valgimigli et al, “Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease”
  185. New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios
  186. Immediate and One-Year Outcome of Percutaneous Intervention of Saphenous Vein Graft Disease With Paclitaxel-Eluting Stents
  187. Comparison of Short- (One Month) and Long- (Twelve Months) Term Outcomes of Sirolimus- Versus Paclitaxel-Eluting Stents in 293 Consecutive Patients With Diabetes Mellitus (from the RESEARCH and T-SEARCH Registries)
  188. Rationale and methods of the integrated biomarker and imaging study (IBIS): combining invasive and non-invasive imaging with biomarkers to detect subclinical atherosclerosis and assess coronary lesion biology
  189. Intracardiac echocardiography guidance during percutaneous transluminal septal myocardial ablation in patients with obstructive hypertrophic cardiomyopathy
  190. Complete myocardial revascularization: between myth and reality
  191. Paclitaxel eluting stents for the treatment of angiographically non‐significant atherosclerotic lesions
  192. Left ventricular unloading and concomitant total cardiac output increase by the use of percutaneous impella recover LP 2.5 assist device during high‐risk coronary intervention
  193. Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction
  194. Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile
  195. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population
  196. Comparison of early outcome of percutaneous coronary intervention for unprotected left main coronary artery disease in the drug-eluting stent era with versus without intravascular ultrasonic guidance
  197. Reply
  198. CD34 + and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive Heart Failure
  199. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty
  200. Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction
  201. High-Dose BoluS TiRofibAn and Sirolimus Eluting STEnt versus Abiciximab and Bare Metal Stent in Acute MYocardial Infarction (STRATEGY) Study—Protocol Design and Demography of the First 100 Patients
  202. Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress
  203. Serum From Patients With Acute Coronary Syndromes Displays a Proapoptotic Effect on Human Endothelial Cells
  204. A Quantitative Approach to the Recycling of α-Tocopherol by Coantioxidants
  205. The EPR study of dialkyl nitroxides as probes to investigate the exchange of solutes between micellar and water phases
  206. Neurohormonal modulation in chronic heart failure
  207. Neurohormonal modulation in chronic heart failure
  208. Oxidative Stress EPR Measurement in Human Liver by Radical-probe Technique. Correlation with Etiology, Histology and Cell Proliferation
  209. Serum Xanthine Oxidase in Human Liver Disease
  210. Left ventricular volumes in liver cirrhosis
  211. Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices
  212. Measurement of oxidative stress in human liver by EPR spin-probe technique
  213. Doppler Ultrasound in Portal Hypertension
  214. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: A long-term prospective study
  215. Splanchnic arterial doppler parameters in portal hypertension
  216. Do Peroxyl Radicals Obey the Principle That Kinetic Solvent Effects on H-Atom Abstraction Are Independent of the Nature of the Abstracting Radical?
  217. Duplex Doppler findings in splenic arteriovenous fistula
  218. Gallstone ileus in Caroli's disease: Ultrasound diagnosis
  219. A case of extracranial vertebral artery dissection with spontaneous recovery
  220. IMO 1228 Superior mesenteric artery Doppler impedance indexes in chronic liver diseases
  221. Reactions of Substituted Boryl Radicals with Nitroalkanes. EPR, Kinetic, and Product Studies